370 related articles for article (PubMed ID: 25473151)
1. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
3. [Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
Stoll-Keller F; Fafi-Kremer S; Wolf P; Doffoël M; Baumert T
Bull Acad Natl Med; 2008 Nov; 192(8):1657-67; discussion 1667-8. PubMed ID: 19445379
[TBL] [Abstract][Full Text] [Related]
4. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
6. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
[TBL] [Abstract][Full Text] [Related]
7. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C virus infection and lipoprotein metabolism.
Aizawa Y; Seki N; Nagano T; Abe H
World J Gastroenterol; 2015 Sep; 21(36):10299-313. PubMed ID: 26420957
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies and pathogenesis of hepatitis C virus infection.
Fafi-Kremer S; Fauvelle C; Felmlee DJ; Zeisel MB; Lepiller Q; Fofana I; Heydmann L; Stoll-Keller F; Baumert TF
Viruses; 2012 Oct; 4(10):2016-30. PubMed ID: 23202451
[TBL] [Abstract][Full Text] [Related]
10. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract][Full Text] [Related]
12. New insights in recurrent HCV infection after liver transplantation.
Hsu SH; Yeh ML; Wang SN
Clin Dev Immunol; 2013; 2013():890517. PubMed ID: 23710205
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
Colpitts CC; Baumert TF
Hepatol Int; 2016 Sep; 10(5):741-8. PubMed ID: 27048616
[TBL] [Abstract][Full Text] [Related]
14. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C.
Crosignani A; Riva A; Della Bella S
World J Gastroenterol; 2016 Jan; 22(4):1393-404. PubMed ID: 26819508
[TBL] [Abstract][Full Text] [Related]
15. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
16. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.
Blaising J; Pécheur EI
Biochimie; 2013 Jan; 95(1):96-102. PubMed ID: 22884392
[TBL] [Abstract][Full Text] [Related]
17. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
18. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.
Grassi A; Ballardini G
World J Gastroenterol; 2014 Aug; 20(32):11095-115. PubMed ID: 25170198
[TBL] [Abstract][Full Text] [Related]
19. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.
Fafi-Kremer S; Fofana I; Soulier E; Carolla P; Meuleman P; Leroux-Roels G; Patel AH; Cosset FL; Pessaux P; Doffoël M; Wolf P; Stoll-Keller F; Baumert TF
J Exp Med; 2010 Aug; 207(9):2019-31. PubMed ID: 20713596
[TBL] [Abstract][Full Text] [Related]
20. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
Annicchiarico BE; Siciliano M; Gasbarrini A
G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
